Stereochemistry | ACHIRAL |
Molecular Formula | CH3O5P |
Molecular Weight | 126.0053 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)P(O)(O)=O
InChI
InChIKey=ZJAOAACCNHFJAH-UHFFFAOYSA-N
InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6)
Molecular Formula | CH3O5P |
Molecular Weight | 126.0053 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic
pyrophosphate that inhibits replication of herpesviruses in
vitro including cytomegalovirus (CMV) and herpes simplex
virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective
inhibition at the pyrophosphate binding site on virusspecific
DNA polymerases at concentrations that do not
affect cellular DNA polymerases. FOSCAVIR does not
require activation (phosphorylation) by thymidine kinase or
other kinases and therefore is active in vitro against HSV
TK deficient mutants and CMV UL97 mutants. Thus, HSV
strains resistant to acyclovir or CMV strains resistant to
ganciclovir may be sensitive to FOSCAVIR.
CNS Activity
Originator
Approval Year
Cmax
AUC
T1/2
Doses
AEs
PubMed
Patents
Sample Use Guides
Usual Adult Dose for CMV Retinitis
Induction therapy: 90 mg/kg IV (90- to 120-minute infusion) every 12 hours or 60 mg/kg IV (minimum 1-hour infusion) every 8 hours over 2 to 3 weeks depending on clinical response
Maintenance therapy: 90 to 120 mg/kg IV (2-hour infusion) once a day
Usual Adult Dose for Herpes Simplex - Mucocutaneous/Immunocompromised Host
Induction therapy: 40 mg/kg IV (minimum 1-hour infusion) every 8 or 12 hours
Duration of therapy: 2 to 3 weeks or until healed
Usual Adult Dose for CMV Gastroenteritis
US CDC, NIH, and IDSA recommendations for the treatment of CMV esophagitis or colitis in HIV-infected patients: 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours
Route of Administration:
Intravenous